BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations.
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Lippincott Williams & Wilkins
Access Rights
info:eu-repo/semantics/closedAccess
DOI
Abstract
Description
Journal or Series
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
WoS Q Value
Scopus Q Value
Volume
41
Issue
16
Citation
Sevindik, Ö. G., Chen, C., Yang, J., Farooqui, M. Z. H. ve Paszkiewicz-Kozik, E. (2023). BELLWAVE-008: A phase 3 study of the efficacy and safety of nemtabrutinib in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without TP53 aberrations. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). Chicago, IL, 02-06 June, 2023.
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
info:eu-repo/semantics/closedAccess
